T. Wagner

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

T. Huizinga, B. Souberbielle, E. Esfandiari, 2017, Arthritis Research & Therapy.

Phase I Dose Escalation Study with the Lewis Y Carbohydrate Specific Humanized Antibody IGN 311

G. Schlimok, G. Himmler, R. Kircheis, 2012 .

Phase I Dose Escalation Study with the Lewis Y Carbohydrate Specific Humanized Antibody IGN311

G. Schlimok, G. Himmler, R. Kircheis, 2011 .

Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM‐CSF monoclonal antibody†

M. Gooderham, K. Papp, J. Szepietowski, 2018, The British journal of dermatology.